Abstract 13797: Effects of Resveratrol Supplementation on Walking Performance in Peripheral Artery Disease: A Randomized Clinical Trial
Introduction: Resveratrol, a phenol found in red wine and grape skin, has been associated with longevity in animals and with improved endothelial function and mitochondrial activity in humans without cardiovascular disease. Resveratrol supplement sales exceed 30 million dollars per year. Recent evidence suggests that lower resveratrol doses may have greater benefits.
Hypothesis: In a randomized trial, we hypothesized that 125 mgs and 500 mgs of resveratrol, respectively, would improve walking performance in people with lower extremity peripheral artery disease (PAD), compared to placebo.
Methods: In the RESveratrol To improve outcomes in Older people with PAD (RESTORE) trial, people age 65 and older with PAD were randomized to one of three groups: 500 mgs resveratrol, 125 mgs of resveratrol, and placebo. The trial was double-blinded. The primary outcome was change in six-minute walk distance at 6-month follow-up. Secondary outcomes were changes in maximal and pain-free treadmill walking distance and brachial artery flow-mediated dilation (FMD).
Results: 66 PAD participants were randomized (mean age- 74.4 ±6.7 years, mean ankle brachial index- 0.67±0.18). The study population included 21 (31.1%) females and 33 (50%) blacks. The table shows results. P values are relative to the placebo group.
Conclusions: These results suggest that resveratrol should not be prescribed to improve walking performance or cardiovascular health in people age 65 and older with PAD.
Author Disclosures: M. McDermott: None. C. Leeuwenburgh: None. L. Ferrucci: None. J.M. Guralnik: None. R. Sufit: None. L. Tian: None. L. Zhao: None. J. Stein: None. Y. Gao: None. S. Anton: None. R. De Cabo: None. M. Criqui: None.
- © 2016 by American Heart Association, Inc.